- Home
- PBFS vs AVIR Comparison
PBFS vs AVIR Comparison
Compare PBFS & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBFS
- AVIR
- Stock Information
- Founded
- PBFS 1889
- AVIR 2012
- Country
- PBFS United States
- AVIR United States
- Employees
- PBFS N/A
- AVIR 56
- Industry
- PBFS Banks
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- PBFS Finance
- AVIR Health Care
- Exchange
- PBFS Nasdaq
- AVIR Nasdaq
- Market Cap
- PBFS 278.5M
- AVIR 252.5M
- IPO Year
- PBFS N/A
- AVIR 2020
- Fundamental
- Price
- PBFS $11.40
- AVIR $2.97
- Analyst Decision
- PBFS
- AVIR Hold
- Analyst Count
- PBFS 0
- AVIR 1
- Target Price
- PBFS N/A
- AVIR $6.00
- AVG Volume (30 Days)
- PBFS 10.6K
- AVIR 441.1K
- Earning Date
- PBFS 05-09-2025
- AVIR 05-12-2025
- Dividend Yield
- PBFS N/A
- AVIR N/A
- EPS Growth
- PBFS 27.31
- AVIR N/A
- EPS
- PBFS 0.80
- AVIR N/A
- Revenue
- PBFS $88,641,000.00
- AVIR N/A
- Revenue This Year
- PBFS N/A
- AVIR N/A
- Revenue Next Year
- PBFS N/A
- AVIR N/A
- P/E Ratio
- PBFS $14.25
- AVIR N/A
- Revenue Growth
- PBFS 21.19
- AVIR N/A
- 52 Week Low
- PBFS $9.27
- AVIR $2.46
- 52 Week High
- PBFS $12.20
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- PBFS 45.96
- AVIR 56.05
- Support Level
- PBFS $11.37
- AVIR $2.78
- Resistance Level
- PBFS $11.85
- AVIR $3.03
- Average True Range (ATR)
- PBFS 0.27
- AVIR 0.17
- MACD
- PBFS -0.03
- AVIR 0.03
- Stochastic Oscillator
- PBFS 6.19
- AVIR 88.03
About PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).